The 1993 Walter Hubert Lecture: the Role of the P53 Tumour-suppressor Gene in Tumorigenesis

Overview

Journal Br J Cancer

Specialty Oncology

Date 1994 Mar 1

PMID 8123467

Citations 97

Authors

A J Levine

M E Perry

A Chang

A Silver

D Dittmer

M Wu

D Welsh

Affiliations

Soon will be listed here.

Abstract

The p53 tumour-suppressor gene is mutated in 60% of human tumours, and the product of the gene acts as a suppressor of cell division. It is thought that the growth-suppressive effects of p53 are mediated through the transcriptional transactivation activity of the protein. Overexpression of the p53 protein results either in arrest in the G1 phase of the cell cycle or in the induction of apoptosis. Both the level of the protein and its transcriptional transactivation activity increase following treatment of cells with agents that damage DNA, and it is thought that p53 acts to protect cells against the accumulation of mutations and subsequent conversion to a cancerous state. The induction of p53 levels in cells exposed to gamma-irradiation results in cell cycle arrest in some cells (fibroblasts) and apoptosis in others (thymocytes). Cells lacking p53 have lost this cell cycle control and presumably accumulate damage-induced mutations that result in tumorigenesis. Thus, the role of p53 in suppressing tumorigenesis may be to rescue the cell or organism from the mutagenic effects of DNA damage. Loss of p53 function accelerates the process of tumorigenesis and alters the response of cells to agents that damage DNA, indicating that successful strategies for radiation therapy may well need to take into account the tissue of origin and the status of p53 in the tumour.

Citing Articles

Intratumor Heterogeneity and Treatment Resistance of Solid Tumors with a Focus on Polyploid/Senescent Giant Cancer Cells (PGCCs).

Mirzayans R, Murray D Int J Mol Sci. 2023; 24(14).

PMID: 37511291 PMC: 10380821. DOI: 10.3390/ijms241411534.

Harpagoside Protects Against Doxorubicin-Induced Cardiotoxicity P53-Parkin-Mediated Mitophagy.

Li W, Wang X, Liu T, Zhang Q, Cao J, Jiang Y Front Cell Dev Biol. 2022; 10:813370.

PMID: 35223843 PMC: 8867983. DOI: 10.3389/fcell.2022.813370.

Genetic Mutations in Young Nonsmoking Patients With Oral Cavity Cancer: A Systematic Review.

Bahethi R, Stepan K, Pinotti R, Li R, Agrawal N, Puram S OTO Open. 2020; 4(4):2473974X20970181.

PMID: 33210069 PMC: 7643225. DOI: 10.1177/2473974X20970181.

Yield of p53 expression in esophageal squamous cell cancer and its relationship with survival.

Sankalecha T, Gupta S, Gaikwad N, Shirole N, Kothari H Saudi J Gastroenterol. 2017; 23(5):281-286.

PMID: 28937022 PMC: 5625364. DOI: 10.4103/sjg.SJG_56_17.

Treatment with a selenium-platinum compound induced T-cell acute lymphoblastic leukemia/lymphoma cells apoptosis through the mitochondrial signaling pathway.

Wu F, Cao W, Xu H, Zhu M, Wang J, Ke X Oncol Lett. 2017; 13(3):1702-1710.

PMID: 28454312 PMC: 5403366. DOI: 10.3892/ol.2017.5666.

References

Werness B, Levine A, Howley P . Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science. 1990; 248(4951):76-9. DOI: 10.1126/science.2157286. View

Sturzbecher H, Maimets T, Chumakov P, Brain R, Addison C, Simanis V . p53 interacts with p34cdc2 in mammalian cells: implications for cell cycle control and oncogenesis. Oncogene. 1990; 5(6):795-81. View

Fields S, Jang S . Presence of a potent transcription activating sequence in the p53 protein. Science. 1990; 249(4972):1046-9. DOI: 10.1126/science.2144363. View

Raycroft L, Wu H, Lozano G . Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science. 1990; 249(4972):1049-51. PMC: 2935288. DOI: 10.1126/science.2144364. View

Malkin D, Li F, Strong L, Fraumeni Jr J, Nelson C, Kim D . Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990; 250(4985):1233-8. DOI: 10.1126/science.1978757. View

Srivastava S, Zou Z, Pirollo K, Blattner W, Chang E . Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature. 1990; 348(6303):747-9. DOI: 10.1038/348747a0. View

Scheffner M, Werness B, Huibregtse J, Levine A, Howley P . The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990; 63(6):1129-36. DOI: 10.1016/0092-8674(90)90409-8. View

Donehower L, Harvey M, Slagle B, McArthur M, Montgomery Jr C, Butel J . Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992; 356(6366):215-21. DOI: 10.1038/356215a0. View

Stenger J, Mayr G, Mann K, Tegtmeyer P . Formation of stable p53 homotetramers and multiples of tetramers. Mol Carcinog. 1992; 5(2):102-6. DOI: 10.1002/mc.2940050204. View

10.

Clarke A, Purdie C, Harrison D, Morris R, Bird C, Hooper M . Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature. 1993; 362(6423):849-52. DOI: 10.1038/362849a0. View

11.

El-Deiry W, Kern S, Pietenpol J, Kinzler K, Vogelstein B . Definition of a consensus binding site for p53. Nat Genet. 1992; 1(1):45-9. DOI: 10.1038/ng0492-45. View

12.

Murray A . Cell cycle. Sunburnt fission yeast. Nature. 1993; 363(6427):302. DOI: 10.1038/363302a0. View

13.

Walworth N, Davey S, Beach D . Fission yeast chk1 protein kinase links the rad checkpoint pathway to cdc2. Nature. 1993; 363(6427):368-71. DOI: 10.1038/363368a0. View

14.

Oberosler P, Hloch P, Ramsperger U, Stahl H . p53-catalyzed annealing of complementary single-stranded nucleic acids. EMBO J. 1993; 12(6):2389-96. PMC: 413469. DOI: 10.1002/j.1460-2075.1993.tb05893.x. View

15.

Dittmer D, Pati S, Zambetti G, Chu S, Teresky A, Moore M . Gain of function mutations in p53. Nat Genet. 1993; 4(1):42-6. DOI: 10.1038/ng0593-42. View

16.

Wu X, Bayle J, Olson D, Levine A . The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 1993; 7(7A):1126-32. DOI: 10.1101/gad.7.7a.1126. View

17.

Lowe S, Ruley H, Jacks T, Housman D . p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 1993; 74(6):957-67. DOI: 10.1016/0092-8674(93)90719-7. View

18.

Finlay C, Hinds P, Tan T, Eliyahu D, Oren M, Levine A . Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol. 1988; 8(2):531-9. PMC: 363177. DOI: 10.1128/mcb.8.2.531-539.1988. View

19.

Lane D, CRAWFORD L . T antigen is bound to a host protein in SV40-transformed cells. Nature. 1979; 278(5701):261-3. DOI: 10.1038/278261a0. View

20.

Linzer D, Levine A . Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell. 1979; 17(1):43-52. DOI: 10.1016/0092-8674(79)90293-9. View